Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meiact in childhood acute rhinosinusitis
NCT01553006Phase 4Unknown
- Sponsor
- Thammasat University
- Start
- Jan 2012
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of cefditoren in acute rhinosinusitis (ARS) (2 arms), sponsored by Thammasat University. Primary endpoint: Sinus symptoms scores at 14 days. Status: unknown.
02
Drugs
cefditoren
03
Conditions
acute rhinosinusitis (ARS)
Beyond the preview
Go deeper on NCT01553006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01553006.